<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl4">
 <label>Table 4</label>
 <caption>
  <p>Costs and expected R&amp;D outcomes from advancing all available vaccine candidates for 11 epidemic infectious diseases from preclinical through to end of phase 2a</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th colspan="3" align="left">
     <bold>Number of confirmed vaccine candidates</bold>
     <hr/>
    </th>
    <th colspan="2" align="left">
     <bold>Expected US$ cost, preclinical through to phase 2a (95% CI)</bold>
     <hr/>
    </th>
    <th colspan="2" align="left">
     <bold>Expected number of phase 2b/3 ready vaccine candidates (95% CI)</bold>
     <hr/>
    </th>
   </tr>
   <tr>
    <th/>
    <th align="left">Preclinical</th>
    <th align="left">Phase 1</th>
    <th align="left">Phase 2</th>
    <th align="left">Low PoS–low cost scenario</th>
    <th align="left">High PoS–high cost scenario</th>
    <th align="left">Low PoS–low cost scenario</th>
    <th align="left">High PoS–high cost scenario</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Ebola</td>
    <td align="left">37</td>
    <td align="left">4</td>
    <td align="left">1</td>
    <td align="left">661 million (297–1200 million)</td>
    <td align="left">1800 million (428–4100 million)</td>
    <td align="left">3 (1–7)
     <xref rid="tbl4fn1" ref-type="table-fn">*</xref>
    </td>
    <td align="left">9 (5–14)
     <xref rid="tbl4fn1" ref-type="table-fn">*</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Zika</td>
    <td align="left">28</td>
    <td align="left">8</td>
    <td align="left">1</td>
    <td align="left">587 million (260–1100 million)</td>
    <td align="left">1500 million (391–3500 million)</td>
    <td align="left">3 (2–6)</td>
    <td align="left">9 (6–13)</td>
   </tr>
   <tr>
    <td align="left">Chikungunya</td>
    <td align="left">20</td>
    <td align="left">5</td>
    <td align="left">2</td>
    <td align="left">424 million (187–768 million)</td>
    <td align="left">1100 million (282–2500 million)</td>
    <td align="left">2 (1–4)</td>
    <td align="left">6 (4–9)</td>
   </tr>
   <tr>
    <td align="left">Lassa</td>
    <td align="left">28</td>
    <td align="left">..</td>
    <td align="left">..</td>
    <td align="left">431 million (183–800 million)</td>
    <td align="left">1200 million (270–2800 million)</td>
    <td align="left">2 (1–5)</td>
    <td align="left">6 (3–9)</td>
   </tr>
   <tr>
    <td align="left">MERS</td>
    <td align="left">21</td>
    <td align="left">4</td>
    <td align="left">..</td>
    <td align="left">389 million (172–703 million)</td>
    <td align="left">1100 million (257–2400 million)</td>
    <td align="left">1 (1–4)</td>
    <td align="left">5 (3–8)</td>
   </tr>
   <tr>
    <td align="left">Marburg</td>
    <td align="left">19</td>
    <td align="left">2</td>
    <td align="left">..</td>
    <td align="left">322 million (142–593 million)</td>
    <td align="left">901 million (210–2000 million)</td>
    <td align="left">1 (1–3)</td>
    <td align="left">3 (2–6)</td>
   </tr>
   <tr>
    <td align="left">Rift Valley fever</td>
    <td align="left">15</td>
    <td align="left">..</td>
    <td align="left">2</td>
    <td align="left">258 million (112–466 million)</td>
    <td align="left">703 million (165–1600 million)</td>
    <td align="left">1 (1–3)</td>
    <td align="left">3 (2–5)</td>
   </tr>
   <tr>
    <td align="left">Nipah</td>
    <td align="left">13</td>
    <td align="left">..</td>
    <td align="left">..</td>
    <td align="left">191 million (82–359 million)</td>
    <td align="left">558 million (116–1300 million)</td>
    <td align="left">0 (0–2)</td>
    <td align="left">2 (1–4)</td>
   </tr>
   <tr>
    <td align="left">CCHF</td>
    <td align="left">6</td>
    <td align="left">1</td>
    <td align="left">..</td>
    <td align="left">95 million (39–179 million)</td>
    <td align="left">279 million (62–620 million)</td>
    <td align="left">0</td>
    <td align="left">0 (0–1)</td>
   </tr>
   <tr>
    <td align="left">SARS</td>
    <td align="left">6</td>
    <td align="left">..</td>
    <td align="left">..</td>
    <td align="left">81 million (34–154 million)</td>
    <td align="left">242 million (47–554 million)</td>
    <td align="left">0</td>
    <td align="left">0 (0–1)</td>
   </tr>
   <tr>
    <td align="left">SFTS</td>
    <td align="left">1</td>
    <td align="left">..</td>
    <td align="left">−</td>
    <td align="left">8 million (2–19 million)</td>
    <td align="left">26 million (2–81 million)</td>
    <td align="left">0</td>
    <td align="left">0</td>
   </tr>
   <tr>
    <td align="left">Total</td>
    <td align="left">194</td>
    <td align="left">24</td>
    <td align="left">6</td>
    <td align="left">3600 million (1600–6600 million)</td>
    <td align="left">9800 million (2400–21 600 million)</td>
    <td align="left">13 (6–34)
     <xref rid="tbl4fn1" ref-type="table-fn">*</xref>
    </td>
    <td align="left">43 (26–70)</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>MERS=Middle East respiratory syndrome. CCHF=Crimean Congo haemorrhagic fever. SARS=severe acute respiratory syndrome. SFTS=severe fever with thrombocytopenia syndrome. R&amp;D=research and development.</p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tbl4fn1">
   <label>*</label>
   <p id="cenpara60">New candidates, as two phase 3 ready candidates already exist.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
